Compare
10x Genomics, Inc. vs Cytek Biosciences, Inc. vs Bio-Rad Laboratories, Inc. vs Revvity, Inc.
| Latest fiscal year | 10x Genomics, Inc. TXG | Cytek Biosciences, Inc. CTKB | Bio-Rad Laboratories, Inc. BIO | Revvity, Inc. RVTY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-28 |
| Revenue | $642.82M | $201.49M | $2.58B | $2.86B |
| Revenue growth (YoY) | +5.2% | +0.5% | +0.7% | +3.7% |
| Gross margin | 69.1% | 51.8% | 51.9% | n/a |
| Operating margin | -9.5% | -20.0% | 1.8% | 12.5% |
| Net margin | -6.8% | -33.0% | 29.4% | 8.4% |
| Net income | -$43.54M | -$66.54M | $759.90M | $241.20M |
| EPS (Diluted) | -$0.35 | n/a | $27.85 | $2.07 |
| Operating cash flow | $136.05M | -$4.69M | $532.20M | $582.93M |
| Free cash flow | $130.12M | -$8.77M | $374.60M | $509.41M |
| Cash & equivalents | n/a | $90.85M | $529.80M | $919.86M |
| Total assets | $1.04B | $461.54M | $10.58B | $12.17B |
| Total liabilities | $245.04M | $119.80M | $3.12B | $4.92B |
| Shareholders' equity | $796.33M | $341.74M | $7.45B | $7.25B |
| Return on year-end equity | -5.5% | -19.5% | 10.2% | 3.3% |
| Shares outstanding | 127.69M | 128.55M | n/a | 112.28M |
Revenue, most recent five fiscal years
| Fiscal year | 10x Genomics, Inc. | Cytek Biosciences, Inc. | Bio-Rad Laboratories, Inc. | Revvity, Inc. |
|---|---|---|---|---|
| Latest | $642.82M Ended 2025-12-31 | $201.49M Ended 2025-12-31 | $2.58B Ended 2025-12-31 | $2.86B Ended 2025-12-28 |
| 1 year earlier | $610.78M Ended 2024-12-31 | $200.45M Ended 2024-12-31 | $2.57B Ended 2024-12-31 | $2.76B Ended 2024-12-29 |
| 2 years earlier | $618.73M Ended 2023-12-31 | $193.01M Ended 2023-12-31 | $2.67B Ended 2023-12-31 | $2.75B Ended 2023-12-31 |
| 3 years earlier | $516.41M Ended 2022-12-31 | $164.04M Ended 2022-12-31 | $2.80B Ended 2022-12-31 | $3.31B Ended 2023-01-01 |
| 4 years earlier | $490.49M Ended 2021-12-31 | $127.95M Ended 2021-12-31 | $2.92B Ended 2021-12-31 | $3.83B Ended 2022-01-02 |